Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
The use of Apisolex polymer excipient has been proven to increase the solubility of certain APIs by as much as 50,000-fold
Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure,
Globally, BRUKINSA is approved in more than 70 countries
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
Enhanced alignment to better serve customers across the entire drug development lifecycle under the Fujifilm Life Sciences brand umbrella with the tagline Partners for Life
Subscribe To Our Newsletter & Stay Updated
